ENGOT OV50 / INNOVATE 3
Samenvatting
ENGOT-ov50/ INNOVATE-3 (EF-28)
Randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.
Primair eindpunt
Overall survival (OS)
Aantal benodigde patiënten
540 (enrollment period 30 months)
Contactgegevens
Ingrid Boere
Deelnemende centra: AMC, Erasmus, MUMC, UMCU, Catharina